# AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

> **NCT00326872** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Neurofibromatosis Type 1
- Plexiform Neurofibroma
- Spinal Cord Neurofibroma

## Interventions

- **DRUG:** Cediranib Maleate

## Key facts

- **NCT ID:** NCT00326872
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2011-08-21
- **Final completion:** 2016-05-31
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Closed due to slow accrual prior to interim analysis.
- **Last updated:** 2017-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326872, "AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00326872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*